ABSTRACT
Purpose: To compare the PRN anti-VEGF injection patterns of four retina specialists with respect to the visual and anatomic outcomes in the management of wet age-related macular degeneration (AMD). Methods: Medical records of patients who received bevacizumab, ranibizumab, and aflibercept anti-VEGF injections (years 2010-2020) by four retina specialists were reviewed for frequency, injection intervals, best corrected visual acuity (BCVA), and central macular thickness, center involved (CMT) for statistical analysis. Outcomes measured were change in logMAR BCVA and CMT from the first to last injection visit. Results: Out of 137 AMD patients, 172 eyes were injected by four retina specialists in PRN fashion. Although all four specialists started the injection at similar baseline BCVA and CMT (p > 0.1), significant differences in mean injection number (9.0, p = 0.0001), injection intervals (5.06 weeks, p = 0.001), and total length of treatments (53.3 weeks, p = 0.0001) were observed. The mean change in logMAR BCVA between the first and last injection was -0.05, -0.22, 0.07, and 0.06 for the four specialists, respectively (p = 0.031), and the mean change in CMT was -53.3, -41.4, -72.7, and -21.9 µm (p = 0.41), respectively. Conclusion: Despite similar baseline criteria for injections by the retina specialists, different anti-VEGF injection regimens were practiced resulting in variations in BCVA and CMT outcomes. This suggests a need in establishing a universally adoptable injection regimen with possible integration of the confounding factors to reduce burden on both patients and retina specialists.
ABSTRACT
PURPOSE: To report a rare case of an intraretinal tuberculoma and associated neuroretinitis. METHODS: The patient was evaluated with various imaging modalities including fundus photography, fluorescein angiography, magnetic resonance imaging, and optical coherence tomography; her extensive laboratory workup returned positive for tuberculosis. RESULTS: After initially presenting with no light perception, 13 weeks of antitubercular therapy allowed for visual acuity recovery to 20/30. CONCLUSION: We demonstrate the spectral domain optical coherence tomography characteristics of an intraretinal tuberculoma.
Subject(s)
Chorioretinitis , Tuberculoma , Female , Fluorescein Angiography/methods , Humans , Multimodal Imaging , Tomography, Optical Coherence/methods , Tuberculoma/diagnostic imagingABSTRACT
PURPOSE: To report the one and two year outcome of cycles of three, monthly anti-VEGF injections given upon reactivation of the disease in eyes with neovascular age-related macular degeneration (nAMD). METHODS: Retrospective study of naïve nAMD cases with more than one year of follow-up, treated with a protocol of cycles of three monthly injections of anti-VEGF drugs upon reactivation. Visual acuity (VA) and central macular thickness (CMT) are the main outcome measures. RESULTS: Twenty-six patients with a mean age of 78.15 ± 9.29 years (57.7% female) were included. The mean follow-up was 30.89 ± 6.95 months. Treatment started with bevacizumab in all patients but in six patients was switched to aflibercept due to inadequate response to intravitreal bevacizumab injection. The mean VA at baseline and at 12 and 24 months was 53.87 ± 21.84, 60.54 ± 21.13, and 53.68 ± 27.16 ETDRS letters, respectively. Patients gained a mean of 6.67 ± 13.7 (p = 0.013, 95% CI= 0.60 to 12.65) and 0.77 ± 15.21 (p = 0.4, 95% CI: -5.65 to 7.2) letters at 12 and 24 months. CMT at baseline, 12, and 24 months was 403.55 ± 147.59, 323.95 ± 79.58, and 298.59 ± 77.161 µm, respectively. The number of injections in the first and second years were 7.65 ± 2.64 and 5.52 ± 3.01, respectively. Three eyes (12.5%) lost > 15 letters at 24 months. CONCLUSION: This protocol can stabilize or improve vision in 87.5% of nAMD patients and can reduce the number of visits.
ABSTRACT
PURPOSE: To present a documented case of development of focal choroidal excavation (FCE) in non-neovascular age related macular degeneration (AMD). METHODS: An 86-year-old female with pachy-choroid was followed clinically for non-neovascular AMD. Successive optical coherence tomography (OCT) scans were reviewed with tracking software. RESULTS: Over the course of follow-up development of a FCE adjacent to a pachy-vessel along with disappearance of the pachy-vessel was documented in OCT. CONCLUSIONS: This case is a documented development of FCE in an eye with pachy-choroid features. The possible mechanism in this scenario may be thrombosis of pachy-vessels.
ABSTRACT
A 43-year-old male with a history of allergic rhinitis on chronic intranasal corticosteroids presented with complaints of a "black band" in his right eye visual field. On examination, he had subretinal fluid and lab tests and imaging studies including optical coherence tomography (OCT) and fluorescein angiography (FA) did not show any evidence of inflammatory, degenerative, or malignant process. He was diagnosed with central serous chorioretinopathy (CSCR). Symptoms improved and the subretinal fluid resolved after the discontinuation of intranasal corticosteroid medication. Intranasal corticosteroids are rarely associated with CSCR. Patients and providers should be aware of the potential risk of vision loss caused by intranasal corticosteroids.
Subject(s)
Central Serous Chorioretinopathy/chemically induced , Glucocorticoids/adverse effects , Triamcinolone Acetonide/adverse effects , Administration, Intranasal , Adult , Glucocorticoids/administration & dosage , Humans , Male , Rhinitis, Allergic/drug therapy , Triamcinolone Acetonide/administration & dosageABSTRACT
We reviewed literature on adverse reactions to intravenous fluorescein angiography using PubMed and found 78 articles in English from 1961 to 2017. The reported rates of adverse reactions were overall 0.083-21.69%, separated into mild (1.24-17.65%), moderate (0.2-6%), and severe (0.04-0.59%). There were 1:100,000 to 1:220,000 deaths. Fluorescein concentration, volume injected, speed of injection, temperature, and contaminants were not correlated with the incidence of reactions. Patient characteristics including other comorbid diseases, allergy history, age, race, and gender showed only an increased rate of reaction in patients with a history of reaction to fluorescein. Although a number of studies examine techniques to reduce adverse reactions to intravenous fluorescein angiography, to date, the only proven method is reviewing allergy history, specifically a history of previous reaction to fluorescein.
Subject(s)
Drug Hypersensitivity/epidemiology , Fluorescein Angiography/adverse effects , Fluorescein/adverse effects , Contrast Media/adverse effects , Fundus Oculi , Global Health , Humans , Incidence , Retinal Diseases/diagnosisSubject(s)
Central Serous Chorioretinopathy/drug therapy , Choroid/diagnostic imaging , Retina/diagnostic imaging , Rifampin/administration & dosage , Administration, Oral , Adult , Central Serous Chorioretinopathy/diagnosis , Dose-Response Relationship, Drug , Fluorescein Angiography/methods , Follow-Up Studies , Fundus Oculi , Humans , Male , Nucleic Acid Synthesis Inhibitors/administration & dosage , Tomography, Optical Coherence/methodsABSTRACT
[This corrects the article DOI: 10.1155/2017/9805145.].
Subject(s)
Immunoglobulin Light Chains/immunology , Multiple Myeloma/complications , Paraproteinemias/complications , Retinal Detachment/etiology , Retinal Perforations/etiology , Retinal Pigment Epithelium/pathology , Aged , Antineoplastic Agents/therapeutic use , Combined Modality Therapy , Dexamethasone/analogs & derivatives , Dexamethasone/therapeutic use , Diabetes Mellitus, Type 2/complications , Drug Therapy, Combination , Glucocorticoids/therapeutic use , Humans , Hypertension/complications , Kidney Transplantation , Lenalidomide/therapeutic use , Male , Multiple Myeloma/diagnosis , Multiple Myeloma/therapy , Oligopeptides/therapeutic use , Paraproteinemias/immunology , Paraproteinemias/therapy , Retinal Detachment/diagnostic imaging , Retinal Perforations/diagnostic imaging , Retinal Pigment Epithelium/diagnostic imaging , Stem Cell Transplantation , Tomography, Optical CoherenceSubject(s)
Carcinoid Tumor/secondary , Choroid Neoplasms/drug therapy , Choroid/pathology , Lung Neoplasms/pathology , Photochemotherapy/methods , Photosensitizing Agents/therapeutic use , Adult , Carcinoid Tumor/diagnosis , Carcinoid Tumor/drug therapy , Choroid Neoplasms/diagnosis , Choroid Neoplasms/secondary , Fluorescein Angiography , Fundus Oculi , Humans , Male , Tomography, Optical CoherenceSubject(s)
DNA, Mitochondrial/genetics , MELAS Syndrome/complications , Retinal Detachment/etiology , Retinal Vessels/diagnostic imaging , Adult , Disease Progression , Female , Fluorescein Angiography/methods , Fundus Oculi , Humans , MELAS Syndrome/genetics , Retinal Detachment/diagnosis , Tomography, Optical CoherenceABSTRACT
Smartphone fundus photography is a simple technique to obtain ocular fundus pictures using a smartphone camera and a conventional handheld indirect ophthalmoscopy lens. This technique is indispensable when picture documentation of optic nerve, retina, and retinal vessels is necessary but a fundus camera is not available. The main advantage of this technique is the widespread availability of smartphones that allows documentation of macula and optic nerve changes in many settings that was not previously possible. Following the well-defined steps detailed here, such as proper alignment of the phone camera, handheld lens, and the patient's pupil, is the key for obtaining a clear retina picture with no interfering light reflections and aberrations. In this paper, the optical principles of indirect ophthalmoscopy and fundus photography will be reviewed first. Then, the step-by-step method to record a good quality retinal image using a smartphone will be explained.
Subject(s)
Fundus Oculi , Ophthalmoscopy/methods , Photography/methods , Smartphone/statistics & numerical data , HumansABSTRACT
OBJECTIVE: To estimate the 5-year incidence of progression rate and regression rate and risk factors for diabetic retinopathy (DR) in a cohort of Lebanese patients with type II diabetes. METHODS: We followed a cohort of 462 Lebanese patients with type II diabetes for over 5 years at the American University of Beirut Medical Center. Patients underwent yearly complete ophthalmic evaluation and fundus photographs and were assessed for the incidence, stage, and evolution of DR using modified Airlie House classification. RESULTS: Among the 462 patients, 281 had no DR at baseline. The 5-year cumulative incidence of any DR was 10% (95% CI: 6-13), and only baseline microalbuminuria correlated with the development of DR (OR = 10.53, 95% CI: 4.39-25.23, p < 0.0001). Among the 181 patients with baseline DR, the worsening and regression rates of DR were 31.5% (95% CI: 25-38) and 9% (95% CI: 5-13), respectively. Microalbuminuria also approached statistical significance as a risk factor for DR worsening (OR = 1.89, 95% CI: 0.97-3.70, p = 0.06). CONCLUSION: The 5-year incidence of DR in this hospital-based cohort is relatively low. Microalbuminuria was independently associated with the incidence and progression of the disease. We recommend to screen patients with type II diabetes for microalbuminuria as prognostic for the development and worsening of DR.
Subject(s)
Radiation Injuries/etiology , Retina/radiation effects , Retinal Diseases/etiology , Sunlight/adverse effects , Atrophy , Fluorescein Angiography , Humans , Male , Middle Aged , Photoreceptor Cells, Vertebrate/pathology , Radiation Injuries/diagnosis , Retinal Diseases/diagnosis , Retinal Photoreceptor Cell Outer Segment/pathology , Retinal Pigment Epithelium/pathology , Tomography, Optical Coherence , Visual AcuityABSTRACT
PURPOSE: We have previously reported that mouse kallikrein (KLK) 22 in the lacrimal and salivary glands is an autoantigen that can induce primary Sjogren syndrome (SS) in rats. In this study, we determine whether the production of antibodies against tissue KLK is specific for SS and whether the antibody can be used as a biomarker for the diagnosis in humans. METHODS: Sera from 11 patients diagnosed with SS, 8 patients with dry eye disease (DED), and 8 normal age/sex-matched controls (NL) were collected for detecting antibodies against tissue KLK1, KLK11, KLK12, and KLK13 by capture enzyme-linked immunosorbent assay. RESULTS: Anti-KLK11 antibody was significantly higher in the SS than in the DED (P = 0.05) and NL (P < 0.01) groups, with no difference in the level of this antibody between the DED and NL groups. In addition, receiver operating characteristic analysis revealed that, at or above an optical density cutoff point of 0.2695, anti-KLK11 antibody has a sensitivity of 82% and a specificity of 94% to distinguish the SS group from the other groups. CONCLUSIONS: Our results suggest that anti-KLK11 might be a novel biomarker for SS in humans. Further investigation is required to confirm this finding and to establish the exact role of KLK11 in the pathogenesis of SS.
Subject(s)
Autoantibodies/blood , Autoantigens/immunology , Serine Endopeptidases/immunology , Sjogren's Syndrome/immunology , Adult , Aged , Aged, 80 and over , Biomarkers , Dry Eye Syndromes/immunology , Enzyme-Linked Immunosorbent Assay , Female , Humans , Immunoglobulin G/blood , Male , Middle AgedABSTRACT
Programmed death ligand-1 (PD-L1) plays a critical role in T-cell regulatory function. Here, we report a newly discovered effect of PD-L1 on angiogenesis. We demonstrate that PD-L1 and its receptor CD80, but not PD-1, are expressed by primary murine lung and heart vascular endothelial cells and the miscrovascular endothelial cell line (MS1) at both the mRNA and protein levels in vitro. The inhibition of PD-L1 or CD80 expression in MS1 cells, by small-interfering RNA transfection, led to a significant up-regulation of vascular endothelial growth factor receptor 2 expression and cell proliferation levels in MS1 cells. Furthermore, MS1 cells were found to have a significantly lower proliferation and vascular endothelial growth factor receptor 2 expression levels when they were co-cultured with PD-L1-expressing normal corneal epithelial cells, as compared to MS1 cells co-cultured with PD-L1(-/-) corneal epithelial cells. In a suture-induced corneal angiogenesis model, we observed a significantly higher level of angiogenic response in PD-L1(-/-) knockout mice as compared to wild-type mice, although there was no significant difference in the expression of inflammatory cytokines (interleukin-1α, interleukin-1ß, or tumor necrosis factor-α) or the infiltration of innate immune cells (neutrophils and macrophages) between the two groups. We conclude that the expression of PD-L1 in both vascular endothelial cells and corneal epithelial cells regulates corneal angiogenesis.